Novartis Investigative Site

Old Point Station, South Carolina 29707

0 studies enrolling now · 3 studies all time

What they study most

Advancing Multiple Sclerosis, Multiple Sclerosis, Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis

Studies at this site

• Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients — Completed
• Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies — Completed
• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. — Completed